Tecan Group AG (CH:TECN)
:TECN
TECN Stock Chart & Stats
CHF127.00
CHF1.00(0.54%)
At close: 4:00 PM EST
CHF127.00
CHF1.00(0.54%)
Day’s Range― - ―
52-Week RangeCHF110.60 - CHF177.50
Previous CloseN/A
Volume42.71K
Average Volume (3M)44.12K
Market Cap
CHF1.63B
Enterprise ValueCHF1.65B
Total Cash (Recent Filing)CHF311.37M
Total Debt (Recent Filing)CHF218.32M
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Aug 19, 2026EPS Estimate
2.9Next Dividend Ex-DateN/A
Dividend Yield2.31%
Share Statistics
EPS (TTM)4.26
Shares Outstanding12,825,883
10 Day Avg. Volume56,389
30 Day Avg. Volume44,118
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.41
Price to Sales (P/S)1.84
P/FCF Ratio15.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF160.65Price Target Upside26.49% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)6.03
Revenue Forecast (FY)CHF878.42M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow leverage gives Tecan durable financial flexibility to fund R&D, support OEM contracts and installed-base service, and execute capital returns (share buyback) without raising material refinancing risk. This balance-sheet conservatism helps absorb cyclical weakness over the next several months.
Resilient Cash GenerationConsistent positive operating cash flow—even during a loss year—supports ongoing service, consumables supply and product rollouts. Reliable cash generation enables continued investment in automation platforms and OEM programs while limiting reliance on new debt for near-term operational needs.
Order Momentum & Product InnovationStrong order intake, a returning Life Sciences segment and recent product launches (Veya workstation, Duo Digital Dispenser) indicate sustainable demand for core automation platforms. Product momentum and bookings support recurring consumables, service revenue and OEM pipeline over the medium term.
Bears Say
Prolonged Revenue Decline & Margin CompressionThree consecutive years of revenue decline alongside sharp operating-margin compression and a swing to a large net loss undermine internal funding and competitive reinvestment. Restoring historical profitability will require sustained revenue recovery or structural cost and pricing improvements.
China And Partnering ExposureMaterial weakness in the Partnering business and China tender delays expose Tecan to region- and partner-specific cycles. Prolonged softness in these channels can reduce recurring consumable and service revenue and amplify volatility in near-term top-line recovery.
Weaker Cash Momentum & Earnings QualityA ~31.6% drop in free cash flow and a loss year driven partly by non-operating items signal deteriorating earnings quality and weaker cash conversion. Continued FCF weakness would constrain R&D, service investments and make sustaining buybacks or cushioning further shocks more difficult.
Tecan Group AG News
TECN FAQ
What was Tecan Group AG’s price range in the past 12 months?
Tecan Group AG lowest stock price was CHF110.60 and its highest was CHF177.50 in the past 12 months.
What is Tecan Group AG’s market cap?
Tecan Group AG’s market cap is CHF1.63B.
When is Tecan Group AG’s upcoming earnings report date?
Tecan Group AG’s upcoming earnings report date is Aug 19, 2026 which is in 144 days.
How were Tecan Group AG’s earnings last quarter?
Tecan Group AG released its earnings results on Mar 16, 2026. The company reported CHF4.26 earnings per share for the quarter, beating the consensus estimate of CHF3.39 by CHF0.87.
Is Tecan Group AG overvalued?
According to Wall Street analysts Tecan Group AG’s price is currently Undervalued.
Does Tecan Group AG pay dividends?
Tecan Group AG pays a Annually dividend of CHF3 which represents an annual dividend yield of 2.31%. See more information on Tecan Group AG dividends here
What is Tecan Group AG’s EPS estimate?
Tecan Group AG’s EPS estimate is 2.9.
How many shares outstanding does Tecan Group AG have?
Tecan Group AG has 12,825,883 shares outstanding.
What happened to Tecan Group AG’s price movement after its last earnings report?
Tecan Group AG reported an EPS of CHF4.26 in its last earnings report, beating expectations of CHF3.39. Following the earnings report the stock price went down -3.374%.
Which hedge fund is a major shareholder of Tecan Group AG?
Currently, no hedge funds are holding shares in CH:TECN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tecan Group AG
Tecan Group AG provides laboratory instruments and solutions for pharmaceutical and biotechnology companies, university research departments, and forensic and diagnostic laboratories. It operates through Life Sciences Business and Partnering Business segments. The company offers liquid handling and automation, microplate readers and washers, consumables, NGS reagents, immunoassays and microbodies, and software; Tecan Laberwax, an automation solution; Resolvex, a smart sample preparation solution for use in genomics, synthetic biology, drug discovery, analytical chemistry, cell biology, protein science, applied markets, and ELISA solutions. It also develops and manufactures laboratory instrument manufacturers with essential components comprising precision pumps, valves, robotic arms, and developer software for life science research, diagnostics, and various other industries; Synergence, platform-based automation solution; and Freedom EVO and Fluent instruments. The company operates in Switzerland and Other European countries, North America, Asia, and internationally. Tecan Group AG was founded in 1980 and is headquartered in Männedorf, Switzerland.
TECN Company Deck
TECN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture. While Tecan reported strong order entry and growth in the Life Sciences business, challenges in China, a decline in the Partnering Business, and external factors such as tariffs and currency impacts posed significant challenges. The company's strategic initiatives in cost reduction and innovation are positive, but the current market environment remains difficult.View all CH:TECN earnings summariesTECN Stock 12 Month Forecast
Average Price Target
CHF160.65
▲(26.49% Upside)
Technical Analysis
Medacta Group SA
―
Siegfried Holding AG
―
Ypsomed Holding AG
―
SKAN Group AG
―
Medartis Holding AG
―
Options Prices
Currently, No data available
---